Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219307 · ClinicalTrials.gov registry record · Phase 3
NOVOCART 3D Treatment Following Microfracture Failure
A Phase 3 study of Articular Cartilage Defect, sponsored by Aesculap Biologics.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT03219307: Active Phase 3 study of Articular Cartilage Defect, sponsored by Aesculap Biologics.
NCT03219307 is a Phase 3 study of Articular Cartilage Defect that is active but no longer recruiting, run by Aesculap Biologics. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03219307, a Phase 3 study of Articular Cartilage Defect, is active but no longer recruiting, sponsored by Aesculap Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
Primary Outcome
Comparison of pain scores from the KOOS questionnaire from baseline
Conditions Studied
Interventions
- COMBINATION_PRODUCT NOVOCART 3D
Study Locations (5)
Illinois
- Rush University Medical Center - Chicago
Ohio
- Ohio State University Wexner Medical Center - Columbus
Utah
- Alpine Orthopaedics - North Logan
Alberta
- University of Alberta - Edmonton
Nova Scotia
- Dalhousie University - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
What the registry record for NCT03219307 still lists
NCT03219307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Articular Cartilage Defect appearing as the primary indexed condition, and to 1 intervention - of which NOVOCART 3D is the first listed.
NCT03219307 lists 5 locations in 5 states (Illinois, Ohio, Utah).
Frequently Asked Questions
What is clinical trial NCT03219307 about?
NCT03219307 is a clinical study titled "NOVOCART 3D Treatment Following Microfracture Failure". This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
What is the current status of trial NCT03219307?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2018-11-30. Estimated completion is 2029-01.
What conditions does trial NCT03219307 study?
This clinical trial studies the following conditions: Articular Cartilage Defect.
What interventions are being tested in trial NCT03219307?
The interventions under investigation include: NOVOCART 3D (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03219307?
This trial is sponsored by Aesculap Biologics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03219307 being conducted?
This trial has 5 study locations across Illinois, Ohio, Utah, Alberta, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Articular Cartilage Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03219307's enrollment target sits among peer trials
30 1918th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI